Clinical Trials Sponsored by Galmed Pharmaceuticals Ltd

Total 4512 results

Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Healthy
Betta Pharmaceuticals Co., Ltd.

Unknown

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Pancreatic Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Non-small-cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Completed

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-small Cell Lung Cancer | Brain Metastases

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Beijing Biostar Pharmaceuticals...

Recruiting

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Esophageal Cancer

China
PeriPharm
Idorsia Pharmaceuticals Ltd.

Not yet recruiting

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada

Insomnia

Canada
JCR Pharmaceuticals Co., Ltd.

Recruiting

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Mucopolysaccharidosis III-A

Germany
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer

Pancreatic Cancer | KRAS P.G12C

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of BPI-452080 in Subjects With Solid Tumors

Renal Cell Carcinoma | Solid Tumor | Von Hippel-Lindau Disease

China
Ascletis Pharmaceuticals Co., Ltd.

Not yet recruiting

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

SARS CoV 2 Infection

United States
Glenmark Pharmaceuticals Ltd. India

Recruiting

To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma

Bronchial Asthma

India
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Lymphoma | HCC | NSCLC | Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12C

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Non-small Cell Lung Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Advanced Colorectal Cancer | Small Intestinal Cancer | Appendiceal Cancer

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
JCR Pharmaceuticals Co., Ltd.

Recruiting

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Mucopolysaccharidosis II

United States, Germany, Spain, France, Brazil, Argentina, Turkey, United Kingdom, Poland, Italy
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Jazz Pharmaceuticals
BeiGene, Ltd.

Active, not recruiting

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)

HER2-amplified Biliary Tract Cancers

United States, Spain, United Kingdom, Korea, Republic of, Canada, China, Italy, Chile, France
Jacobio Pharmaceuticals Co., Ltd.

Active, not recruiting

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

NSCLC | Solid Tumor

China
Jacobio Pharmaceuticals Co., Ltd.

Completed

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Healthy Subjects

China
BioNova Pharmaceuticals (Shanghai) LTD.

Completed

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

GVHD, Chronic

China
JCR Pharmaceuticals Co., Ltd.

Enrolling by invitation

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

Mucopolysaccharidosis II

United States
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Non-Small Cell Lung Cancer | EGFR Gene Mutation

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Non-Small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
JCR Pharmaceuticals Co., Ltd.

Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II

Japan
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (ICAPE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors

Solid Tumors

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
TaiwanJ Pharmaceuticals Co., Ltd

Completed

Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

Autoimmune Hepatitis

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Healthy

China
Foresee Pharmaceuticals Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Prostatic Neoplasms

Korea, Republic of, United States, Lithuania, Slovakia, Czechia
Taiwan Mundipharma Pharmaceuticals Ltd.

Completed

Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain (STOP Pain)

Pain | Cancer

Taiwan
Betta Pharmaceuticals Co., Ltd.

Unknown

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Lung Cancer | ROS1 Gene Rearrangement

China
Betta Pharmaceuticals Co., Ltd.

Completed

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (Convince)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalating Study of BPI-3016 in Healthy Subjects

Healthy Subject

China
Foresee Pharmaceuticals Co., Ltd.

Completed

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Healthy

Netherlands

3

Subscribe